ALK-Abello A/S is a prominent pharmaceutical company focused on allergy immunotherapy. The company's values revolve around providing effective, patient-centric solutions to allergy-related conditions. With a strong commitment to research and development, ALK-Abello A/S strives to constantly innovate and improve allergy treatments. The company's corporate philosophy emphasizes scientific expertise, quality, and safety in all aspects of their operations. ALK-Abello A/S aims to enhance the quality of life for individuals suffering from allergies through their dedication to excellence and continued advancements in allergy immunotherapy.

ALK-Abello A/S is primarily present in several countries and regions around the world. The company has a strong presence in Europe, with significant operations in Denmark, where it is headquartered, as well as in other European countries like Germany, France, and the United Kingdom. ALK-Abello A/S also has a significant presence in North America, with operations in the United States and Canada. Additionally, the company has expanded its presence in Asia, with operations in countries such as China and Japan. Overall, ALK-Abello A/S has a global footprint that spans multiple regions, allowing it to serve a diverse range of markets and customers.

ALK-Abello A/S, a renowned pharmaceutical company, has attained several significant milestones over the years. The company has successfully developed and commercialized various immunotherapy products, focusing on the treatment of severe allergies. Notably, ALK-Abello A/S achieved regulatory approvals for its flagship product, GRAZAX®, in multiple countries, revolutionizing the field of allergy treatment. Furthermore, the company has expanded its global presence by establishing subsidiaries and partnerships worldwide, allowing them to reach a wider patient base. ALK-Abello A/S continues to innovate and conduct groundbreaking research, constantly striving to enhance the lives of individuals affected by allergies.

ALK-Abello A/S, founded in 1923, is a leading global pharmaceutical company specializing in allergy immunotherapy. With a rich history spanning nearly a century, ALK-Abello has become synonymous with innovation and excellence in the field of allergen immunotherapy. The company is committed to advancing and constantly improving the treatment of respiratory allergies, such as allergic rhinitis and allergic asthma. ALK-Abello focuses on developing and producing a wide range of high-quality, patient-friendly allergy vaccines, including subcutaneous, sublingual, and tablet-based treatments. This Danish company is dedicated to tackling the burden of allergies worldwide, improving the quality of life for allergy sufferers through its extensive portfolio of products and research efforts.

ALK-Abello A/S, a leading pharmaceutical company specializing in allergy immunotherapy, faces competition in the market from several key players. Some of the main competitors of ALK-Abello A/S include companies like Stallergenes Greer, Allergy Therapeutics, Circassia Pharmaceuticals, and Merck KGaA. These companies also operate in the field of allergy immunotherapy and offer a range of products and treatments. ALK-Abello A/S engages in rigorous research and innovation to maintain its competitive edge and provide effective solutions to individuals suffering from allergies.

ALK-Abello A/S is primarily active in the pharmaceutical industry.

The business model of ALK-Abello A/S revolves around the development, manufacturing, and sale of allergy immunotherapy treatments. As a leading pharmaceutical company, ALK-Abello focuses on providing allergy sufferers with effective, patient-tailored solutions. They have a strong portfolio of products, including subcutaneous and sublingual allergy immunotherapy vaccines, which help build immunity and alleviate allergic symptoms. ALK-Abello A/S combines research and innovation to deliver high-quality and safe allergy treatments, helping individuals improve their quality of life. Their commitment to addressing the unmet needs of allergy patients has made them a trusted name in the industry.

Det ALK-Abello A/S P/E-forhold er 47,35.

ALK-Abello A/S KUV er 6,36.

AlleAktien Kvalitetsscore for ALK-Abello A/S er 4/10.

Den forventede ALK-Abello A/S omsætning er 5,76 mia. DKK.

Den forventede ALK-Abello A/S indtjening er 772,51 mio. DKK.

ALK-Abello A/S is a Danish pharmaceutical company specialized in allergic diseases since its founding in 1923. With its innovative research results and comprehensive portfolio of high-quality allergological products, it is one of the leading companies in the industry. ALK-Abello is divided into various business areas, all specialized in the manufacturing and distribution of products for the diagnosis and treatment of different allergic diseases. These include immunotherapy, allergy diagnostics, plant breeding, and sales & marketing. In the field of immunotherapy, ALK-Abello focuses on the development, manufacturing, and marketing of allergen vaccines. These are offered in the form of injection solutions or sublingual tablets and serve for the long-term treatment of allergic symptoms. ALK-Abello's products are known for their high efficacy, safety, and compatibility and are distributed in more than 30 countries worldwide. The allergy diagnostics area encompasses a wide range of diagnostic tests that can be used for the identification of allergies and determination of allergen doses. This includes in vitro tests such as blood tests or the RAST method, as well as in vivo tests like the prick test. ALK-Abello is a leader in the development of diagnostics and offers both standard and customized test systems. In the field of plant breeding, ALK-Abello specializes in breeding natural allergen sources. The goal is to produce allergens of suitable quality and concentration for the manufacturing of allergen vaccines. The company has several specialized plantations in different countries and is also involved in researching alternative allergen sources such as mold or house dust mites. Finally, the sales and marketing team of ALK-Abello is crucial for the company's business model. It ensures that ALK-Abello's products are available worldwide, advises doctors and patients on treatment options, and is responsible for communication with regulatory authorities. Overall, the business model of ALK-Abello is based on a holistic approach that combines research, development, production, and marketing. The company focuses on the needs of allergy sufferers and works closely with specialist doctors and research institutions worldwide. With its high-quality products and experienced team of specialists, ALK-Abello is well-equipped to continue playing an important role in the fight against allergic diseases.

ALK-Abello A/S udbetaler et udbytte på 0 DKK fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for ALK-Abello A/S, eller selskabet udbetaler ikke udbytte.

ISIN'en for ALK-Abello A/S er DK0060027142.

WKN for ALK-Abello A/S er A0H0J1.

Tickeren for ALK-Abello A/S er ALK B.CO.

I løbet af de sidste 12 måneder betalte ALK-Abello A/S en dividende på 5,00 DKK . Dette svarer til et dividendeudbytte på omkring 3,02 %. For de kommende 12 måneder vil ALK-Abello A/S sandsynligvis betale en dividende på 0 DKK.

Udbytteafkastet for ALK-Abello A/S er i øjeblikket 3,02 %.

ALK-Abello A/S betaler kvartalsvis udbytte. Dette uddeles i månederne april, april, april, april.

ALK-Abello A/S betalte udbytte hvert år i løbet af de sidste 6 år.

For de kommende 12 måneder forventes der dividender på 0 DKK. Dette svarer til et dividendeafkast på 0 %.

ALK-Abello A/S bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på ALK-Abello A/S fra den 20.3.2017 på 5 DKK, skulle du have haft aktien i din portefølje før ex-datoen den 16.3.2017.

Udbetalingen af det sidste udbytte blev foretaget den 20.3.2017.

I løbet af 2023 udbetalte ALK-Abello A/S 0 DKK i form af dividender.

Udbytterne fra ALK-Abello A/S udbetales i DKK.